1. Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes.
- Author
-
Park J, Song H, Moon S, Kim Y, Cho S, Han K, Park CY, Cho SW, and Oh CM
- Subjects
- Animals, Male, Republic of Korea epidemiology, Humans, Mice, Inbred C57BL, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental complications, PPAR alpha agonists, PPAR alpha metabolism, Tumor Necrosis Factor-alpha metabolism, Time Factors, Databases, Factual, Signal Transduction drug effects, Myocardium metabolism, Myocardium pathology, Female, Hospitalization, Middle Aged, Aged, Inflammation Mediators metabolism, Inflammation Mediators blood, Risk Factors, Ventricular Function, Left drug effects, Fenofibrate therapeutic use, Fenofibrate pharmacology, Obesity drug therapy, Heart Failure drug therapy, Diabetic Cardiomyopathies prevention & control, Diabetic Cardiomyopathies etiology, Diabetic Cardiomyopathies drug therapy, Hypolipidemic Agents therapeutic use
- Abstract
Background: Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. This study aimed to investigate the effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, on the obese- and diabetes-related cardiomyopathy., Methods and Results: We used db/db mice and high fat diet-streptozotocin induced diabetic mice to investigate the underlying mechanisms of fenofibrate's beneficial effects on heart function. Fenofibrate reduced fibrosis, and lipid accumulation, and suppressed inflammatory and immunological responses in the heart via TNF signaling. In addition, we investigated the beneficial effects of fenofibrate on HF hospitalization. The Korean National Health Insurance database was used to identify 427,154 fenofibrate users and 427,154 non-users for comparison. During the 4.22-year follow-up, fenofibrate use significantly reduced the risk of HF hospitalization (hazard ratio, 0.907; 95% CI 0.824-0.998)., Conclusions: The findings suggest that fenofibrate may be a useful therapeutic agent for obesity- and diabetes-related cardiomyopathy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF